



MEMBERS SECTION	
Other Sections	▶
Quicklinks	▶
My Favorites	▶
My Protocols	▶
Website Index	
Clinical Trials	▶
Membership	▶
Workbenches	▶
Member Roster	
Policies & Manuals	
Administrative Forms	
Minutes	
IRB	
QA/Audits	
Serious Adverse Events	
Bulletin Board	
FAQs	
Newsletters	
Group Meeting	
Young Investigators	
Links	
Contact Us	
Logoff	

Protocol Development

[Add to My Favorites >](#)

Status:

Study Number:

Disease Committee:

Treatment:
 13-cis retinoic acid
 5-Fluorouracil
 5-FUDR
 S06U78
 ST4 Modified Vaccinia Ankara

Study Coordinator:

Keywords:

[Add new Protocol](#)



MEMBERS SECTION

- [Other Sections](#) ▶
- [Quicklinks](#) ▶
- [My Favorites](#) ▶
- [My Protocols](#) ▶
- [Website Index](#)
- [Clinical Trials](#) ▶
- [Membership](#) ▶
- [Workbenches](#) ▶
- [Member Roster](#)
- [Policies & Manuals](#)
- [Administrative Forms](#)
- [Minutes](#)
- [IRB](#)
- [QA/Audits](#)
- [Serious Adverse Events](#)
- [Bulletin Board](#)
- [FAQs](#)
- [Newsletters](#)
- [Group Meeting](#)
- [Young Investigators](#)
- [Links](#)
- [Contact Us](#)
- [Logoff](#)

Admin Protocol

[Add to My Favorites >](#)

Status: Under Development Tabled Activated

Protocol Number:

Title:

Short Title:

Protocol Coordinator:

Primary Disease Committee:

Involved Disease Committees

- | | |
|---|---|
| <input type="checkbox"/> Brain Cancer | <input type="checkbox"/> Immunomolecular Therapeutics |
| <input type="checkbox"/> Breast Cancer | <input type="checkbox"/> Leukemia |
| <input type="checkbox"/> Cancer Control | <input type="checkbox"/> Lung Cancer |
| <input type="checkbox"/> Committee on Special Populations | <input type="checkbox"/> Lymphoma |
| <input type="checkbox"/> Early Therapeutics | <input type="checkbox"/> Melanoma |
| <input type="checkbox"/> Gastrointestinal Cancer | <input type="checkbox"/> Myeloma |
| <input type="checkbox"/> Genitourinary Cancer | <input type="checkbox"/> Other |
| <input type="checkbox"/> Gynecologic Cancer | <input type="checkbox"/> Sarcoma |
| <input type="checkbox"/> Head and Neck Cancer | |

Treatment

Current Listing:

Study Coordinators

Assigned Study Coordinators

Add Coordinators

Remove Coordinators

Available Study Coordinators

- Abidi, Muneer H. [31829]
- Advani, Anjali S. [31045]
- Ahmad, Syed [29486]
- Albain, Kathy [11103]
- Alberts, David S. [6033]
- Allen, Jeffrey W. [37492]
- Appelbaum, Frederick R. [6304]
- Bagramian, Robert A. [39324]
- Baker, Amanda F. [37247]
- Baker, Laurence H. [04655]

Other Participants

Assigned Participants

Add Participant

Remove Participant

Available Participants

- Ahmad, Syed A. [29486]
- Albain, Kathy [11103]
- Alberts, David [06033]
- Anderson, Gernet L. [37808]
- Appelbaum, Frederick R. [06304]
- Arbogast Kylee J. [30819]
- Bangs, Rick [42811]
- Baranowski, Karen [29188]
- Barce, Jean [26173]
- Berlogie, Bart [13305]

Date of Capsule Approval: [Example: 5/1/2005]

Enter Roster Number of Study Coordinators or Participants: (00000, 00000, 00000)

Add a Dev Protocol

Cancel

Protocol #:	SWOG tes	
Priority #:		
Title:		
Disease Committee:	Immunomolecular Therapeutics	
SCs: Drs.		
Notes:		
I. CAPSULE SUMMARY:		
It is the responsibility of the Study Coordinator to make sure that all capsule summary form requirements are completed prior to submission of the summary for executive review. (See Capsule Summary Template for requirements)		
Approval Date		
Comments		
II. PROTOCOL DEVELOPMENT:		
All of these steps must be completed before a protocol can be activated.		
a. Letter of Intent:		
Phase II w/NCI-supplied drug OR go to II.c		
Primary Committee's Review	Submission	Approval
Comments		
b. Concept Submission Form:		
Phase III only		
Review	Submission	Approval
Comments		
c. Initial Protocol Draft/Review:		
This process may be repeated until the final protocol is drafted.		
Protocol Review	Date/N/A	
Study Coordinators/Committee Chair(s)		
Statistical Center		
Other Committee SCs (if needed)	v	
Drug Company (if needed)		
Other Reviews		
Draft Forms Inserted		
Ops Consistency Check		
NCI Protocol Submission Worksheet		
PRC Review		
Intergroup CTSU: QARC: RPC:		
Comments		
d. Final Protocol Draft/Review:		
Protocol Review	Date/N/A	
Study Coordinators/Committee Chair(s)		
Statistical Center		

Others	
CTEP/DCP (copy for IND and contracts, if needed)	Submission: Consensus Review Received: Consensus Review Response: Approval on hold (if applicable): Final Approval:
CIRB (if needed)	Submission: CIRB Review Received: CIRB Response Submitted: Approval:
Final Ops Consistency Check	
Final PRC Review (if needed)	
Activation Amend (CTEP)	
Final Forms Inserted	
FFS Inserted	
Activation Memo/HIPAA	
Web Documents Prepared	
Database Flags Set	
Comments	
III. ADMINISTRATIVE: (if needed) Contract and IND will be completed by Dir. of Ops and Pharm. Liaison.	
Budget for Drug Distribution	Date finalized:
Budget for Additional Support	Date finalized:
Budget for Correlative Studies	Date finalized:
Contract Signed	Date finalized:
IND Assigned	Date finalized:
Other Last Minute Issues?	Membership: Intergroup: Financial: Correlates: Drug Issues: Other:
Comments	
IV. ACTIVATION:	